Signal Genetics Closes $9M Public Offering of Stock | GenomeWeb

NEW YORK (GenomeWeb) – Signal Genetics announced today the closing of the public offering of its common shares, raising $9 million in gross proceeds. 

The Carlsbad, Calif.-based molecular diagnostics firm offered 3,214,285 shares of its stock at $2.80 per share and has granted the offering's underwriters a 45-day overallotment option to purchase up to 482,142 shares of its common stock. Aegis Capital and Chardan Capital Markets are the joint book-running managers on the offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.